Seoyoung Kim, MD, DSc

Associate Professor of Medicine
BWH Div of Pharmacoepidemiology and Pharmacoeconomics
Boston, Massachusetts, United States

AbbVie (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Bristol-Myers Squibb (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Pfizer (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Roche (Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)

Presentation(s):

Contemporary Trends in the Utilization of Second-line Pharmacological Therapies for Type 2 Diabetes in the United States
Friday, August 26, 2022
5:30 PM – 5:45 PM CEST
Predictors of Effectiveness of First-line Biologic Disease Modifying Antirheumatic Drug(s) (bDMARD) or Targeted Synthetic DMARD (tsDMARD) Treatment with a Tumor Necrosis Factor Inhibitor in Patients with Rheumatoid Arthritis
Saturday, August 27, 2022
1:30 PM – 1:35 PM CEST
Cardiovascular Outcomes in Patients with Type 2 Diabetes Who Added Either GLP1 Receptor Agonists or DPP4 Inhibitors to SGLT2 Inhibitor Therapy
Sunday, August 28, 2022
8:45 AM – 9:00 AM CEST
Cardiovascular Effectiveness of SGLT2 Inhibitors: Head-to-head Comparisons
Sunday, August 28, 2022
9:15 AM – 9:30 AM CEST
Concurrent Use of Prescription Opioids with Other Medications and Risk of Fall and Fracture in Rheumatoid Arthritis Patients
Sunday, August 28, 2022
1:30 PM – 1:45 PM CEST
The Comparative Safety of Individual SGLT2 Inhibitors and the Risk of Diabetic Ketoacidosis
Sunday, August 28, 2022
2:00 PM – 2:15 PM CEST
Risk of Hypoglycemia with Sodium Glucose cotransporter-2 Inhibitors vs. Alternative Glucose Lowering Medications in Patients with and Without Baseline Use of Insulin or Sulfonylurea
Sunday, August 28, 2022
2:30 PM – 2:45 PM CEST